drugset
drugset / Trial / NCT00629525

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

NCT00629525 ↗

Phase 2 Completed 35 enrolled Daniel George, MD Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).

Timeline

Start
2005-08
Primary completion
2009-12
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg Oral

Indications

hormone-resistant prostate carcinoma